samedan logo
home > ict > autumn 2020 > taking a fresh look at ctmss as an integral part of managing clinical trials
International Clinical Trials

Taking a Fresh Look at CTMSs as an Integral Part of Managing Clinical Trials

As the number of clinical trials grow, clinical trial management systems’ (CTMSs') complexity increases, and regulations surrounding them continue to evolve. These intuitive, innovative systems stand ready to demonstrate their true potential in the conduct of future clinical trials.

CTMS History

CTMSs appeared in the 1990s, when they were adopted by biotechnology and pharmaceutical companies as an essential tool in the management of clinical development and operations.

CTMSs have a broad scope with their ability to store centralised enterprise information on clinical trials consisting of product assets, clinical protocols and trials, patient enrolment, tracking quality issues during conduct, project milestones, monitoring of clinical sites, investigator payments, and organisation contacts and team members. This places the role and utility of a CTMS at the centre of conducting clinical trials, according to good clinical practice guidelines, and forms the essential backbone of a management control system for the organisation, in essence, the ‘conductor’ of an

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Daljit Cheema, Founder and CEO of PHARMASEAL, is an experienced strategic Chief Technology Officer with 25 years of pharmaceutical sector experience, and a proven track record of driving business growth through technology innovation, change, and implementation. Daljit led the Perceptive Informatics Technology division managing global software product development, IT operations, and programme management, driving strategic differentiation for competitive advantage. He founded PHARMASEAL in 2016 to create an integrated management platform to support the governance and control of clinical trials, and provide enterprise technology that is highly usable, affordable, and rapid to implement.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Injection vials for vaccines for protection against Covid-19

Düsseldorf, July 02, 2020 The vaccines under development to protect against Covid-19 are, like many other drugs, filled in so-called injection or vials made of type 1 borosilicate glass, also known as vials. The large worldwide demand for vials is met by the Gerresheimer Group's plants in Europe, America and Asia, where they are manufactured to high quality standards for customers in the pharmaceutical industry. The Company has already received initial orders for vials for drugs and vaccines against Covid-19.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement